Xeris Biopharma Holdings, Inc. (XERS) · Oct 14, 2026 · Other events
Patent litigation — Two infringement actions tied to newly granted ’502 patent
Xeris filed patent infringement lawsuits over Keveyis, seeking to block generic dichlorphenamide competition—but the commercial payoff remains uncertain.
Xeris is a commercial-stage specialty biopharma building growth around Recorlev and Gvoke while Keveyis remains a meaningful, mature contributor; Keveyis generated $47.6 million in 2025 revenue, down from $49.5 million in 2024. The filing adds a defensive legal step around a mature product. Xeris has now sued two groups of potential generic competitors after receiving a new patent covering Keveyis. 〔0〕 That could help preserve Keveyis revenue if the patent survives and the defendants are blocked or delayed, but the filing creates no immediate sales, exclusivity ruling, or cash inflow.
The strategic signal is useful, but the outcome is unresolved. The complaints seek injunctions and damages, yet they only allege infringement; they do not establish that the patent will be upheld or that generic entry will ultimately be prevented. 〔1〕 Because the earlier patent-development direction was already public, the lawsuits are the new step; the economic value depends on subsequent court decisions rather than this announcement itself.
Bottom line: This strengthens Xeris’s effort to defend Keveyis, but it is an uncertain legal process rather than an immediate business win. The event matters mainly because Keveyis is still a sizable revenue stream, even as the company’s growth story increasingly rests on Recorlev and Gvoke.
Court proceedings over the ’502 patent
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!